- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Zydus Lifesciences gets CDSCO panel nod to conduct bioequivalence study of Eltrombopag for oral suspension

New Delhi: Zydus Lifesciences has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the bioequivalence study of Eltrombopag for oral suspension 12.5 mg and 25 mg.
This came after Zydus Lifesciences presented the proposal for a grant of permission to manufacture and market Eltrombopag for Oral Suspension 12.5mg and 25mg along with a bioequivalence study protocol and justification for a waiver of the Phase-III clinical trial before the committee.
The committee noted that Eltrombopag for Oral Suspension 12.5mg and 25mg is already approved in the US, UK, and Europe and also that the tablet dosage form is already approved in India. Eltrombopag for oral suspension, 12.5 mg and 25 mg, will be helpful in the dose titration.
Eltrombopag is an oral medication used to treat low platelet counts in adults and children with chronic immune thrombocytopenia (ITP). ITP is a blood disorder that can cause unusual bleeding or bruising. Eltrombopag works by binding to the thrombopoietin receptor, which signals the bone marrow to produce more platelets, increasing the number of cells that help blood clot.
Eltrombopag is used to treat thrombocytopenia (low platelets in the blood) in patients with a blood disorder called chronic immune thrombocytopenia (ITP). This medicine is used after a splenectomy (surgery to remove the spleen) and other medicines (e.g., steroids or immunoglobulin) have not worked well enough.
At the recent SEC meeting held on 6th March 2025, the expert panel reviewed the proposal for the grant of permission to manufacture and market Eltrombopag for Oral Suspension 12.5mg and 25mg along with the bioequivalence study protocol and justification for the waiver of the Phase-III clinical trial.
After detailed deliberation, the committee recommended granting permission to conduct a bioequivalence study as per the protocol presented by the firm.
In accordance with the above, the expert panel suggested that the firm should submit a BE report to CDSCO for further necessary action.
Also Read: Eris Lifesciences gets CDSCO Panel nod To Initiate Phase III CT of Esaxerenone Tablets
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751